Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$2.2M
1M shares
52-week range
$2.45 – $66.50
1% from low
Exchange
NASDAQ
ADRC
Borrow rate
256.57%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $674.0K | $343.0K | $578.0K | $699.0K | $381.0K | $0 | $0 |
| Cost of revenue | $9.4M | $7.8M | $6.1M | $4.7M | $5.1M | $4.1M | $5.4M | $184.9K |
| Gross profit | −$7.4M | −$7.2M | −$5.7M | −$4.1M | −$4.4M | −$3.7M | −$5.4M | −$184.9K |
| Gross margin | -382.9% | -1063.6% | -1669.1% | -705.2% | -631.2% | -967.5% | — | — |
| R&D | $9.4M | $7.8M | $16.1M | $4.7M | $5.1M | $4.1M | $5.4M | $3.7M |
| Operating income | −$11.8M | −$11.3M | −$23.0M | −$7.0M | −$8.9M | −$8.0M | −$9.2M | −$8.3M |
| EBITDA | −$10.7M | −$9.5M | −$22.2M | −$5.7M | −$8.3M | −$7.2M | −$9.1M | −$8.1M |
| Net income | −$10.4M | −$10.1M | −$22.2M | −$5.5M | −$7.7M | −$7.1M | −$5.7M | −$6.2M |
| Net margin | -535.0% | -1496.3% | -6469.1% | -944.6% | -1095.3% | -1858.0% | — | — |
| EPS (diluted) | -292803790.00 | -35095575.00 | -33209775.00 | -4661590.00 | -4770680.00 | -69640.00 | -3705.65 | -400.00 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5687 | $-0.00 | $-0.00–$-0.00 | 1 |
| 2027 | $2843 | $-0.00 | $-0.00–$-0.00 | 1 |
Forward consensus · source: Financial Modeling Prep
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
www.biodexapharma.comNo one on the platform currently holds BDRX.
No tracked institution reports a position in BDRX as of their last filing.
| Execution date | Ratio |
|---|---|
| 2026-04-06 | 1-for-5reverse |
| 2025-07-31 | 1-for-10reverse |
| 2024-10-04 | 1-for-25reverse |
| 2023-07-05 | 1-for-80reverse |
| 2023-03-27 | 1-for-4reverse |
No one on the platform has traded BDRX yet.
| $44M |
| — |
| GLMDGalmed Pharmaceuticals Ltd. | $0.57 | -0.45% | $3M | — |
| GNPXGenprex, Inc. | $0.51 | +2.06% | $824080 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$BDRX Expanding Phase 3 SERENTA Trial into Canada; 73 Patients Enrolled Thus Far https://buff.ly/dSuddV1
View on StockTwits ↗$BDRX the action is smooth enough to raise eyebrows.
View on StockTwits ↗$BDRX level 2 wide open now! Is this the run coming now?!!!
View on StockTwits ↗$BDRX low float about to fly! Biotech 🚀
View on StockTwits ↗$BDRX shorts are about to get squeezed today 😬
View on StockTwits ↗$BDRX really liking 700k chairs $2.70! $ILLR about to send $QUCY Saint share structure similar s same strategy! Price target $5 plus $AMS we take people by surprise. $1.3m insider buying a $2.28. Very underrated.
View on StockTwits ↗Pre Market Top Gainers PT2 $BDRX $SHPH $RCT $WYHG $ALTG
View on StockTwits ↗Pre Market Top Gainers PT2 $BDRX $SHPH $RCT $WYHG $ALTG
View on StockTwits ↗$BDRX gap filled! Time to fly. Squeeze these shorts 🩳
View on StockTwits ↗Will $SDOT and $SHPH send this low floater $BDRX flying???
View on StockTwits ↗$BDRX congrats if you banked. Take your money and run away. This IS a megascam.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.